We measured glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and the concentrating capacity of the kidneys in children after autologous BMT. Twenty-six patients had received TBI in their conditioning regimen and 14 patients had received chemotherapy only. Median follow-up was 10 years. Mean After this initial decrease, GFR and ERPF remained essentially unchanged in both groups. The mean concentrating capacity of the kidneys was normal before and after BMT. In seven patients chronic renal impairment developed after BMT (GFR Ͻ70 ml/min/1.73 m 2 ). All had received TBI. They had also received more nephrotoxic antibiotics than the other patients. We conclude that TBI was the principal cause of deterioration of renal function after BMT, possibly by limiting compensatory hyperperfusion and resulting in a fall in GFR. Antibiotic treatment may have contributed.
lead to severe hemodynamic disturbances, most notably hepatic veno-occlusive disease (VOD) and sepsis, and with the use of nephrotoxic medication. [1] [2] [3] [4] [5] [6] Other (rare) causes include the tumor lysis syndrome, and after autologous BMT also the nephrotoxicity associated with infusion of the stored marrow. 7, 8 Chronic renal impairment, which is usually evident within 3-12 months post BMT, is commonly attributed to delayed effects of the radiochemotherapy used in the conditioning regimen prior to BMT. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The pathoclinical presentation is reminiscent both of radiation nephritis and of the hemolytic-uremic syndrome. 13, 19 Other factors involved in BMT that may cause chronic renal damage include nephrotoxic antibiotics and infections. 5 After allogeneic BMT the nephrotoxicity of cyclosporin A and chronic GVHD also need to be considered. 20, 21 Although chronic renal impairment in children was described at an early date, to our knowledge, only one pediatric study has focused on its long-term development (after allogeneic BMT). [9] [10] [11] 13, 22 Hence, little is known about whether the renal damage that is evident within the first year after BMT leads to progressive loss of renal function or to ultimate stabilization. A few studies of adult bone marrow recipients have addressed this issue, but since data suggest that compared with adult kidneys, developing kidneys may be more vulnerable to the preparative regimen before BMT, children should be studied separately. 10, 15, 16, 23 Also, assessment of renal function should be based on methods that are accurate in the BMT setting. 24 We present a prospective study of renal function in 40 children treated with autologous BMT, with or without TBI, for hematological malignancies or lymphomas. Renal function was assessed at regular intervals, using accurate and reproducible means of measurement. Median follow-up was 10 years. Although the focus was on long-term renal function, we also described acute renal complications of the transplantation procedure. The influence of TBI and nephrotoxic antibiotics on long-term renal function was of particular interest.
Patients and methods
Between October 1985 and August 1997, 50 patients less than 18 years of age were treated with autologous BMT (n = 49) or syngeneic BMT (n = 1) at the University Hospital of Uppsala, which serves as a tertiary referral center for pediatric oncology. Ten patients relapsed within 6 months after BMT, none of whom had evidence of renal impairment at the time of relapse. Here, we included the 40 patients who were followed up for at least 6 months after BMT. They all entered our follow-up program, which lasts for a minimum of 10 years after BMT. Baseline data are summarized in Table 1 . The children with ALL had received treatment according to the Swedish Child Leukemia Group protocol that applied at the time of diagnosis, and the children with AML had received treatment according to the current AML protocol of the NOPHPO (Nordic Society for Pediatric Hematology and Oncology). 25, 26 Details of the conditioning regimens have been thoroughly recorded elsewhere. 27 In short, patients with ALL and lymphoblastic lymphoma (LBL) were conditioned with prednisolone, teniposide, daunorubicin, vincristine, cyclophosphamide (always together with mesna for bladder protection), and cytarabin, plus TBI. In most patients (n = 22) TBI was given in a single fraction on day −1 as two opposed 5 MV X-ray anterior-posterior fields with lung shielding. The total absorbed dose in the center of the patient was 7.5 Gy (dose rate 15 cGy/min), and the maximum dose to the lungs and kidneys was also 7.5 Gy ± 5%. The four patients who had most recently undergone transplantation were treated with fractionated TBI, consisting of 12 Gy in six fractions over 3 days (dose rate 15 cGy/min). These 26 patients are referred to as the +TBI group. Patients with AML received busulfan and cyclophosphamide (BUCY regimen), while patients with large cell anaplastic lymphoma and Hodgkin's disease received BCNU, etoposide, cytarabin, and cyclophosphamide. These 14 patients are referred to as the −TBI group. One patient with Hodgkin's disease had received fractionated irradiation (total dose 25 Gy) to the thorax and the upper abdomen 1 month before BMT. Harvested bone marrow was cryopreserved with 10% DMSO and was infused on day 0. All children received oral aciclovir and cotrimoxazole for 3 months after BMT, prophylactically. Four patients in the +TBI group and five patients in the −TBI group relapsed during follow-up, with a median time to relapse of 15 months in both groups. The median long-term follow-up was 120 months in the +TBI group and 54 months in the −TBI group. Evaluation of renal function before BMT included measurement of the glomerular fil- (1) TBI = total body irradiation; ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; LBL = lymphoblastic lymphoma; LCAL = large cell anaplastic lymphoma; HD = Hodgkin's disease. tration rate (GFR), effective renal plasma flow (ERPF), serum creatinine concentration, and the concentrating capacity of the kidneys, and also dipstick urinalysis. GFR was estimated by single-injection clearance using 51 Cr-EDTA, except in the first year of the program, when GFR was measured by endogenous creatinine clearance, usually in duplicate. ERPF was introduced during the fourth year of the program and was estimated by single-injection clearance using 131 iodine-hippurate ( 131 IOH). During the hour preceding the investigation the children were orally hydrated (13 ml/kg body weight). Children less than 7 years of age were given a 51 Cr-EDTA dose of 74 kBq/kg body weight and those aged 7 years and older received 37 kBq/kg body weight, as intravenous injections. During the period 5-180 min after the injection seven blood samples were drawn from another vein than that used for the injection. The thyroid gland was then blocked by 50 or 100 mg KI orally in children below or above 7 years of age, respectively. Two hours later an intravenous injection of 131 IOH at a dose of 18 kBq/kg body weight was given. During the following 60 min another five blood samples were taken in the same manner as described above. The mean reference values ± s.d. for GFR and ERPF obtained in a control group at our laboratory were 119 ± 9 and 640 ± 90 ml/min/1.73 m 2 , respectively. These reference values are based on estimates of 51 Cr-EDTA and of 131 IOH clearance in 23 children aged 7-17 years in whom 131 IOH radio-renography was also performed to rule out possible impairment of renal function. These children were admitted to hospital for reasons such as enuresis, urethra tract syndrome, trauma to the back, and abdominal pain. No signs of impaired renal function were found in these children. The filtration fraction (FF) was calculated from the quotient GFR Ϭ ERPF (mean reference value 19%). The concentrating capacity of the kidneys was determined by the desmopressin test, with intranasal administration of 20 g desmopressin in children and 40 g in adolescents. This test was introduced during the second year of the program. Routine laboratory and clinical assessment also included hematocrit, platelet count, haptoglobin, lactate dehydrogenase, and blood pressure. After transplantation, GFR and ERPF were determined routinely at follow-up visits after 6, 12, 24, 36, 60 and 120 months. Concentrating capacity was determined at the 6-month follow-up, then annually up to 5 years after BMT. Owing to procedural difficulties these tests were not carried out in all patients at every follow-up, but for our principal parameter (GFR) the number of drop-outs was small (80% of scheduled 51 Cr-EDTA clearances were performed). All other tests were repeated 3, 6, 9 and 12 months after BMT, and then annually. No patient was lost to follow-up or excluded from the study.
Peak serum creatinine values, results of liver function tests, and information on infections and the use of potentially nephrotoxic antibiotics (aminoglycosides (mainly amicacin), intravenous vancomycin, and amphotericin B) during the early post-transplant period (defined as the period from day 0 until discharge; median 28 days, range 18-69 days) were collected from the transplantation charts. Acute renal impairment was defined as at least doubling of the baseline serum creatinine during the early post-trans-plant period. A diagnosis of chronic renal impairment was defined as GFR Ͻ70 ml/min/1.73 m 2 у 6 months after BMT. Hepatic VOD was diagnosed according to established criteria. 28 
Statistics
As evident from Figures 1-4 and Figure 6 the principal changes in renal function occurred during the first 6 months after BMT. For this reason, and as the follow-up time differed between patients, the univariate statistical analyses were restricted to this period of time. The paired t-test was used to compare pre-transplant values with those obtained 6 months after BMT, and Student's t-test was applied to compare pre-transplant values between groups. Repeated measures ANOVA was used to compare pre-transplant values of serum creatinine with those obtained 3 and 6 months after BMT. The Bonferroni procedure was used for adjusting for multiple comparisons. Ninety-five percent confidence intervals (CI) were calculated at all points in time. The Mann-Whitney U test was used for non-normally distributed unpaired variables. Intergroup comparison of categorical variables was made with Fisher's exact test. Pearson's product moment correlations and Spearman's rank correlations were calculated in analyses of relationships between normally and not normally distributed variables, respectively. Multiple regression was performed to examine the contribution of nephrotoxic antibiotics (entered as dummy variables) to the change in GFR, while adjusting for age and pre-transplant GFR. Here, in order to avoid missing values, the dependent variable in the regression model was the mean value for each patient calculated from measurements performed 6, 12 and 24 months after BMT. All calculations were made with SPSS 10.0.
Ethics
This study was approved by the Ethics Committee of the Medical Faculty, Uppsala University.
Results

Acute renal impairment
No patient had a serum creatinine value outside the normal range before BMT. Only a 4-year-old girl in the +TBI group with ALL in CR2 experienced acute renal impairment according to the definition. Her renal function recovered rapidly and was normal at the last follow-up 10 years after BMT.
No procedure-related deaths occurred during the early post-transplant period and major clinical complications were few. Almost all patients had episodes of fever during neutropenia, necessitating antibiotic treatment. Severe infections were sparse, however. In the +TBI group 50, 29 and 29% received treatment with intravenous vancomycin, aminoglycosides, and the combination of the two, respectively. The corresponding figures in the −TBI group were 42, 62 and 42%. One patient in the +TBI group received treatment with amphotericin B. One patient in the −TBI Bone Marrow Transplantation group suffered hepatic VOD with little concomitant renal impairment.
Long-term follow-up
The mean GFR values before BMT were close to our mean reference value of 119 ml/min/1.73 m 2 both in the +TBI group and in the −TBI group ( Table 2 ). The mean GFR decreased significantly 6 months after BMT in the +TBI group (P Ͻ 0.001). Multiple regression analysis showed that only treatment with the combination of aminoglycosides and intravenous vancomycin contributed significantly to the decrease in GFR in the +TBI group (R 2 = 0.48, P = 0.015) (B = −32 [CI −54,−10], P Ͻ 0.01). Age was not a significant predictor of low GFR in this analysis. In the −TBI group the GFR did not decrease significantly (P = 0.22). Analysis showed no influence of nephrotoxic antibiotics on GFR in this group. After 6 months the mean GFR stabilized in both groups without further changes ( Figure 1) .
The mean ERPF values before BMT (based on five patients in each group) were high compared with our mean reference value of 640 ml/min/1.73 m 2 . Age was found to be significantly correlated with ERPF in the −TBI group (r s = −0.9, P = 0.037), but not in the +TBI group. There were no significant correlations between ERPF and GFR in either of the groups before BMT. After BMT, the mean ERPF showed a nonsignificant decrease in the +TBI group (P = 0.064) and in the −TBI group (P = 0.24). As before BMT, age correlated strongly with ERPF in the −TBI group (r s = 1.0, P Ͻ 0.001). The patients with the lowest ERPF 6 Table 2 Renal function before BMT and 3 to 6 months after BMT months after BMT were consistently those with the lowest GFR at the same point in time (see Figure 2 . There was a strong correlation between ERPF and GFR which was significant in the −TBI group (r = 0.95, P = 0.015) and almost achieved significance in the +TBI group (r = 0.85, P = 0.065). As shown in Figures 2 and 3 , ERPF seemed to stabilize in most patients in both groups after 12 months (note the shorter follow-up in the −TBI group).
Before BMT the mean FF was low in the +TBI group and increased significantly 6 months after BMT in this group (P = 0.049). The mean serum creatinine concentrations before BMT were within the normal range in both groups (Figure 4) . The tendency to a higher serum creatinine concentration in the −TBI group may be due to a higher median age than in the +TBI group. The values obtained 3 and 6 months after BMT in the +TBI group were significantly higher than the pre-transplant value (P Ͻ 0.01), but there was no significant difference between the values obtained 3 and 6 months after BMT. There were no significant changes in the −TBI group. After 6 months the serum creatinine concentration seemed to increase as expected in growing children, in both groups. The mean concentrating capacity was within the normal range in both groups before BMT and remained unchanged during follow-up ( Figure 5) .
No patient had a GFR Ͻ70 ml/min/1.73 m 2 before transplantation. Seven patients in the +TBI group (27%) developed chronic renal impairment after BMT (see Table 3 ). In all of these patients the lowest GFR value was recorded 6 months after BMT (mean 56 ml/min/1.73 m 2 , range 38-67). After improving to some extent, GFR then stabilized, albeit at a reduced level ( Figure 6 ). ERPF also stabilized at a reduced level (Figure 2) . The mean values for the latest GFR and ERPF after a median of 60 months of follow-up were 76 ml/min/1.73 m 2 (range 67-85) and 448 ml/min/1.73 m 2 (range 288-617), respectively. The concentrating capacity was normal during follow-up. In four patients there was an increase in serum creatinine during follow-up (first observed 4-6 months after BMT) and in five patients anemia developed (first observed after 3-6 months). Four patients developed microscopic hematuria and three patients proteinuria. Hemolytic parameters (lactate dehydrogenase and haptoglobin) and the platelet count were normal in all patients. Serum creatinine normalized within the first year and the hematocrit normalized We observed no other clinical signs of renal disease during the first years after BMT. Nine years after BMT patient No. 5 showed an increased serum creatinine (125 mol/l) and hypertension (140/105 mm Hg), and is currently being treated with enalapril. A needle biopsy was taken from his left kidney (which had shown the most marked functional deterioration on renography) 1 year after BMT and histopathological examination showed mesangial hyperplasia and separation of endothelial cells from the basement membranes in the glomeruli. Within the +TBI group there were no significant baseline differences between the chronic renal impairment group and the other patients. A larger proportion of the patients in the chronic renal impairment group had received the combination of aminoglycosides and intravenous vancomycin during the early post-transplant period (16 vs 71%, P = 0.014). Also, the only patient who received amphotericin B was included in the chronic renal impairment group.
Discussion
Only one patient experienced acute (and mild) renal impairment in our study. This low incidence compares very favorably with previous reports. In two pediatric studies the incidence rates were 50% and 34%, respectively. 5, 6 The main reason for this discrepancy between our incidence and the latter figures is probably that most patients in the latter studies underwent allogeneic BMT, whereas all our patients were autografted. This assumption is supported by the results of Gruss et al, 3 who reported that the incidence of acute renal impairment was significantly higher after allogeneic than after autologous BMT (36% vs 6.5%, P Ͻ 0.001). Lane et al 4 studied the clinical course in 30 children requiring dialysis early after BMT and found that the dialysis group included fewer autologous than allogeneic transplants. In our study, proposed risk factors for acute renal impairment were sparse. [1] [2] [3] [4] [5] [6] For instance, only one patient experienced hepatic VOD, severe infections were uncommon, and amphotericin B was used in only one patient.
In 1991 we published a follow-up study of renal function comprising both adults and children who had undergone autografting at our center. 12 We have now followed our pediatric cohort for a substantially longer time (median 10 years). We have confirmed our previous observations of a rapid decline in glomerular function, as reflected by an increase in serum creatinine and a concomitant decrease in GFR. These changes were significant only in the +TBI group and were already apparent after 3 months (serum creatinine). After these initial changes, the GFR stabilized and the serum creatinine seemed to increase as expected in growing children. 29 Distal tubular function, on the other hand, as assessed by the concentrating capacity of the kidneys, remained unaffected throughout the study. This is in keeping with experimental findings which suggest that glomerular changes predominate at clinically relevant radiation doses. 30 A similar development of GFR was described by Berg and Bolme, 22 who evaluated long-term renal function in children after allogeneic BMT for acute leukemia or severe aplastic anemia (including TBI at 10 Gy given in one fraction in children with leukemia). They found a significant decrease in mean GFR (inulin clearance) 1 year after BMT, and GFR continued to be significantly lower than that of the controls throughout the study (5 years).
Since 1989 we have added ERPF to the tests routinely performed. Although this test was carried out in fewer patients, it nevertheless yielded some interesting results. In contrast to Berg and Bolme, 22 who found that both the mean ERPF and the mean GFR values before BMT were significantly decreased in children with ALL compared with controls, but not in children with AML, we found that ERPF was higher than expected in the +TBI group (mostly patients with ALL treated for a relapse) and tended to be high also in the −TBI group (mostly patients with AML).
To our knowledge, similar data have not been reported previously, one reason probably being that ERPF has rarely been evaluated in children with cancer. GFR, on the other hand, was normal in both groups (and not increased proportionately as could be expected), leading to a decreased filtration fraction. After BMT, ERPF tended to decrease to a relatively greater extent than GFR in the +TBI group (this again is in contrast to the results of Berg and Bolme, who found no further decrease in ERPF after BMT), leading to a significantly higher filtration fraction. The expected relationship between ERPF and GFR was also restored. One tentative and simplistic explanation for these findings is that the kidneys may have been damaged during treatment of the primary diseases and that ERPF was compensatorily increased to keep the glomerular filtration within the normal range. After BMT, this compensatory mechanism might have been impaired (mainly in the +TBI group), and ERPF and GFR would be decreased. It is difficult to decide which event is primary and alternative interpretations of the relationships between GFR, ERPF and FF are possible. The strong correlation between ERPF and age in the −TBI group, but not in the +TBI group, both before and after BMT has not, to our knowledge, been reported before. We have no explanation for this unexpected finding.
In an individual analysis of our long-term survivors, we found that seven of our 40 patients were given a diagnosis of chronic renal impairment. Guinan et al 10 reported that seven of 21 children with ALL developed renal impairment after autologous BMT. The high incidence was attributed to the combination of intensive chemotherapy (teniposide, cytarabine and cyclophosphamide) and TBI (12-14 Gy over 3-4 days) in the conditioning regimen. In our study too, TBI appeared to be an important risk factor for the development of chronic renal impairment. That is, all patients who developed chronic renal impairment had received TBI in their conditioning and, as mentioned above, the decline in glomerular function was significant only in the irradiated group. It should be noted, however, that the groups also differed in other important ways which may have influenced the outcome; for instance, they had different diagnosed diseases and consequently received different cytostatic treatments both before and in conjunction with BMT. 31 Other findings support the notion that TBI may be of importance. The onset of renal impairment 3-6 months after BMT and the biphasic development of renal function observed in all patients in the renal impairment group are similar to observations described for radiation nephritis, where the mechanism is thought to be endothelial damage with the long latent period related to the slow turnover of endothelium. 15, 16, 32 The renal biopsy changes in one patient have been described as typical of radiation injury. 32 This patient also displayed an increased serum creatinine and hypertension 9 years after BMT, a latency period possibly analogous to that for classic chronic radiation nephropathy as described by Luxton and Kunkler. 33 If, then, TBI is the most probable cause of renal impairment in our patients, it remains to be explained why only seven out of 26 patients developed renal impairment in the +TBI group, when all patients had received the same treatment and the baseline characteristics were very similar. The only apparent difference was that the patients in the renal impairment group had received more nephrotoxic antibiotics (a combination of vancomycin and aminoglycoside) during the early posttransplant period. Vancomycin and aminoglycoside are known to be more nephrotoxic when given in combination than when given separately. 34 Here, this combination may have potentiated the effect of radiation. From a series of clinical and experimental studies, Cohen and co-workers have described a renal syndrome in adults termed bone marrow transplantation nephropathy (BMT Np), characterized by reduced GFR, hypertension and anemia. [14] [15] [16] The clinical, laboratory and histopathological presentations of BMT Np, which is reminiscent of acute radiation nephritis as originally described by Luxton and co-workers, points to conditioning TBI as the major cause of this syndrome. 18, 33 However, Luxton identified the renal tolerance dose as being about 20 Gy -a higher dose than that used in BMT today. One explanation for this discrepancy may be that Luxton used longer interfractionation intervals, allowing radiation damage to repair between fractions. Another explanation could be that today's intensive chemotherapy regimens, used both before and in conjunction with BMT, may potentiate radiation, as has been shown for some cytotoxic agents in experimental BMT NP. 35, 36 Our finding that the patients who developed chronic renal impairment had received more antibiotic treatment may perhaps be of interest in this context.
In conclusion, the incidence of acute renal impairment was low in our pediatric study group. Renal function showed a biphasic pattern, with some deterioration during the first 6 months after BMT and stabilization at a decreased level thereafter. Chronic renal impairment was observed only in patients who had received TBI in their conditioning regimen. Antibiotic treatment shortly after BMT may have contributed to the renal damage in these patients. Persistent hematuria and/or proteinuria in five patients and late hypertension in one patient indicate ongoing renal disease. This, together with animal data indicating that further deterioration can be anticipated more than 10 years after TBI, emphasizes the need for further follow-up in these patients. 37 
